Patents by Inventor Clarence J. Peters

Clarence J. Peters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds
    Patent number: 8193152
    Abstract: An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: June 5, 2012
    Assignees: The Board of Regents of the University of Texas System, SciClone Pharmaceuticals, Inc.
    Inventors: Eric C. Mossel, Cynthia W. Tuthill, Alfred R. Rudolph, Clarence J. Peters
  • Reverse genetic system for rift valley fever virus and uses thereof
    Patent number: 8084248
    Abstract: The present invention describes a reverse genetic system for Phlebovirus such as Rift Valley fever virus. This system comprised of RNA expression plasmids and protein expression plasmids. Additionally, the present invention also discloses the modification of this system to generate a recombinant virus that expresses a non-viral foreign gene. Furthermore, the present invention discloses the use of this system in the development of anti-Rift Valley fever virus vaccines, screening of antivirals testing for anti RVF immune response and developing marker vaccines for Rift Valley fever virus. We also claim the utility of this approach to other phleboviruses.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: December 27, 2011
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Shinji Makino, Tetsuro Ikegami, Clarence J. Peters, Sungyong Won
  • Treatment or Prevention of Hemorrhagic Viral Infections with Immunomodulator Compounds
    Publication number: 20090143313
    Abstract: An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.
    Type: Application
    Filed: October 27, 2005
    Publication date: June 4, 2009
    Applicant: SciClone Pharmaceuticals, Inc.
    Inventors: Eric C. Mossel, Cynthia W. Tuthill, Alfred R. Rudolph, Clarence J. Peters
  • Transgenic Mouse Lines Expressing Human Ace2 and Uses Thereof
    Publication number: 20090083865
    Abstract: Animal models for severe acute respiratory syndrome-coronavirus infection of humans are needed to elucidate SARS pathogenesis and develop vaccines and antivirals. Transgenic mice were developed expressing human angiotensin-converting enzyme 2, a functional receptor for the virus, under the regulation of a global promoter. A transgenic lineage, designated AC70, was among the best characterized against SARS coronavirus infection, showing weight loss and other clinical manifestations before reaching 100% mortality within 8 days after intranasal infection. Inflammatory mediators were also detected in these tissues, coinciding with high levels of virus replication. In contrast, infected transgene-negative mice survived without showing any clinical illness.
    Type: Application
    Filed: January 11, 2007
    Publication date: March 26, 2009
    Inventors: Teh-Sheng Chan, Shinji Makino, Clarence J. Peters, Chien-Te K. Tseng